Skip to content

End-of-life distress: all studies

Page 22 of 40: studies 211 to 220 of 392, newest first. Back to the end-of-life distress overview

Research

Attitudes Toward Psychedelic-Assisted Therapies for Cancer-Related Psychosocial Symptoms: A Multi- Stakeholder Analysis

Research Square August 19, 2025 Haley D M Schuman, Julie M Deleemans, Tina Nguyen et al. preprint

Abstract Background Psychedelic-assisted therapy (PAT) is gaining attention as a potential treatment for cancer-related psychosocial symptoms. While growing evidence highlights its promise, little is known about how different stakeholder groups perceive its use in oncology and palliative care. Objectives This study aimed to assess stakeholder-specific perspectives on PAT, including attitudes,...

577. CLINICAL EVIDENCE AND APPLICATIONS OF PSYCHEDELICS FOR MENTAL ILLNESSES

The International Journal of Neuropsychopharmacology August 1, 2025 Hiroe Tani

Abstract Background Psychedelics have long been explored as potential treatments for mental illnesses. Since the mid-20th century, clinical trials of psychedelics such as LSD for depression and anxiety in terminally ill patients have been conducted. In the 21st century, revived and accelerated efforts to promote the proper use of psychedelics in the medical field have led to increasingly...

Radiation therapy patients' interest in psychedelic-assisted therapy: results of a survey.

Radiation oncology (London, England) July 21, 2025 Jino Park, Rufus Banks, Akul Munjal et al.

Comorbid mental health symptoms impact 30-40% of cancer patients, significantly compromising treatment adherence and increasing mortality rates. Among patients undergoing radiation therapy, which is delivered with palliative intent in nearly half of all cases and for those nearing end-of-life, these rates may be even higher. Emerging research underscores the promising potential of...

Explore the effect of psilocybin on depression and anxiety

Arts, Culture and Language July 6, 2025 Yutong Song

Psilocybin, also known as “magic mushrooms,” is naturally found in psychedelic compound from different types of mushrooms. The utility of psilocybin for spiritual and therapeutic purposes has already go through several centuries. Scientific research on these compounds gained traction in the mid-20th century, the increasing interest in the possible therapeutic benefits of psilocybin has led to...

Stephen Ross: Psychedelic-assisted therapies for difficult-to-treat psychiatric and medical disorders

Psychedelics June 10, 2025 Stephen Ross

Professor Stephen Ross is a prominent faculty member in the Departments of Psychiatry and Child and Adolescent Psychiatry at the New York University (NYU) Grossman School of Medicine who has transformed the landscape of psychedelic research since 2006. In this Genomic Press Interview, Dr. Ross reveals how as co-director of the NYU Langone Center for Psychedelic Medicine and director of its...

Exploring Fears of Death and Dying Using Network Analysis

Mindfulness June 4, 2025 Cailen J. Calkin, Nirbhay N. Singh, Oleg N. Medvedev 1 citation

Fear of death is often pathologised, yet little research has examined its unique links to different aspects of an individual’s life. This study investigated the unique associations among fear of death, psychological distress, mindfulness, compassion, life limiting illness, spirituality, meaning in life, and self-esteem using network analysis. It also explored the potential influence of...

Practitioner perspectives on extended difficulties and optimal support strategies following psychedelic experiences: A qualitative analysis

Research Square May 13, 2025 Eirini K. Argyri, Joy Krecké, Oliver Robinson et al. 2 citations preprint

Abstract Background As the use of psychedelics increases in both therapeutic and non-clinical settings, reports of extended post-experience difficulties have also emerged. While many individuals integrate their experiences effectively, others face persistent challenges. Despite growing recognition of these issues, there is limited research on best practices for mitigating and addressing...

DOI: 10.21203/rs.3.rs-6303856/v1 (opens in new tab) Full text (opens in new tab) Qualitative analysis Qualitative research Management science Medical education +1

5-MeO-DMT

May 1, 2025 Angelica Ukaigwe, Abhishek Chauhan, S. Vinod Kumar

Abstract 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a psychoactive compound found in the parotid gland venom of the Sonoran Desert toad, Incilius alvarius, and certain seeds, leaves, and barks within the Amazonian rainforest. Similar to DMT containing ayahuasca, 5-MeO-DMT has become newly integrated as a spiritual sacrament in certain churches, offering a psychedelic experience to process...

Psilocybin

May 1, 2025 Jessi Humphreys, Lou Lukas, Yvan Beaussant et al.

Abstract Psilocybin, a naturally occurring psychoactive compound found in more than 200 mushroom species, has an enduring history of use in sacred rituals of Indigenous healers worldwide. With selective serotonin receptor binding, activation of the serotonergic neurological system enables psilocybin to potentiate neuroplasticity, enabling individuals to engage in meaning-making from psychedelic...

Radiation Therapy Patients’ Interest in Psychedelic-assisted Therapy: A Prospective Survey Study

Research Square April 16, 2025 Jino Park, Rufus Banks, Akul Munjal et al. preprint

Abstract Background Comorbid mental health symptoms impact 30–40% of cancer patients, significantly compromising treatment adherence and increasing mortality rates. Among patients undergoing radiation therapy, which is delivered with palliative intent in nearly half of all cases and for those nearing end-of-life, these rates may be even higher. Emerging research underscores the promising...